Table 2 Relationship between postchemotherapy absolute serum CA125 levels and survival in ovarian cancer
From: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
First Author, Year, Study Place | Data Collection | Study Design | Sample Size | Groups being Compared | RR/HR, (95% CI), P-Value | Conclusion | Variables Adjusted for |
|---|---|---|---|---|---|---|---|
Kim HS, 2008, South Korea [45] | Jan 1997 to March 2007 | Retrospective study | 123 | < 10 U/ml, 10--21 U/ml and > 21 U/ml | 2.51(1.06-5.92), 0.027 3.13 (1.14-8.61), < 0.001 | The serum CA125 level after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy may be a good prognostic factor for survival in complete responders | Residual tumor, chemotherapy cycles |
Juretzka MM, 2007, USA [46] | 1984 to 1998 | Retrospective cohort study | 241 | CA125 ≤ 12 U/ml vs > 12 U/ml | 1.41 (1.05--1.91), 0.0248 | CA125 level at the end of primary therapy was a predictor of overall survival and progression free survival | FIGO stage, Histology, grade |
Riedinger JM, 2007, France [47] | 1988 to 1996 | Multicentric retrospective study | 494 | ≤ 35 kU/l, > 35 kU/l | Uni-2.7 (2.2--3.3), < 0.0001 Multi-1.27 (0.94--1.71), NS | CA125 change after first course of chemotherapy was independent prognostic factor for both achievement of pathological complete response and overall survival. | Age, Histology FIGO stage, residual tumor |
Badulescu F, 2005, Romania [48] | 2000 to 2002 | Prospective study | 40 | NA | NA, < 0.05 | The response evaluation criteria based on the blood levels variations of CA125 antigen are a better instrument for the estimation of the compared prognosis with the RECIST criteria | Age, FIGO stage, RECIST criteria |
Van Dalen A, 2000, Europe [5] | 1994 to 1997 | Prospective multicentric study | 213 | ≤ 25 kU/L, > 25 kU/L | 5.6 (2.65--11.90), < 0.0001 | CA125 level of 25 kU/L on completion of three courses of chemotherapy is a good indicator of 2-year overall survival | FIGO stage, Histology, grade, TPS levels |
Ron IG, 1994, Israel [41] | Feb 1987 to Dec 1990 | Prospective study | 48 | ≤ 35 U/ml, > 35 U/ml | NA, < 0.0001 | Patients with CA125 below 35 U/ml after 2 courses had a significantly longer median and disease-free survival than those whose CA125 dropped to normal after the third or a later cycle | Age, FIGO stage, histology, grade, residual tumor, ascites, prechemotherapy CA125 |
Fisken J, 1993, UK [49] | NA | Retrospective study | 58 | 4 quartiles < 55 U/ml, 58-221 U/ml, 228-434 U/ml, > 450 U/ml | < 0.0005 | CA125 was a highly significant predictor of both progression free and overall survival after the first cycle and throughout primary chemotherapy | Residual disease, age, tumor grade, performance status, ascites |
Redman CW, 1990, U.K. [50] | March 1986 to March 1988 | Consecutive case series | 50 | ≤ 35 U/ml, > 35 U/ml | NA, 0.0009 | Serum CA125 after two courses gave the greatest discrimination between patients alive at 12 months and those who did not survive that long | Age, FIGO stage, histology, grade, residual disease |